Treatment of irritable bowel syndrome by homoeopathy

Efficacy of individualized homoeopathic medicines in 50-millesimal potency in adult patients suffering from Irritable Bowel Syndrome with its miasmatic analysis: A Double-blind, Randomised, Placebo-controlled trial - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/06/088181

Enrollment

Registered

2025-06-03

Start date

Unknown

Completion date

Unknown

Last updated

2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K58- Irritable bowel syndrome

Interventions

Intervention1: Individualised homoeopathic medicines in 50-millesimal potency with concomitant care.: In 50-millesimal potencies, one medicated globule of no.10 is to be dissolved in 100 ml of distil

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients fulfilling Rome IV diagnostic criteria for IBS (recurrent abdominal pain that occurs an average of at least 1 day/week and is associated with two or more of the following three features: (1) related to defecation (relief or worsening), (2) associated with a change in frequency of stool, or (3) associated with a change in form (appearance) of stool) 2. Literate patients with the ability to read Bengali, Hindi, and/or English.

Exclusion criteria

Exclusion criteria: 1. Patients having clinical features like unexplained weight loss, bleeding PR, and persistent diarrhoea. 2. Patients having disease symptoms secondary to organic causes like celiac disease, Inflammatory bowel disease and lactose malabsorption, etc. 3. Any major gastrointestinal surgery in the last 6 months 4. Currently receiving standard therapy for IBS and/or homeopathic treatment for any chronic condition(s) especially in last 6 weeks 5. Diagnosed cases of unstable psychiatric complaints or other systemic diseases affecting the quality of life 6. Pregnant, lactating, and puerperal women 7. Self-reported immune-compromised conditions and 8. Substance abuse and/or dependence. 9. Simultaneous participation in any other clinical trial

Design outcomes

Primary

Measure	Time frame
IBS- Severity Scoring System(IBS-SSS)Timepoint: At baseline, and every month, up to 3 months	—

Secondary

Measure	Time frame
IBS-Quality of Life(IBS-QOL)Timepoint: At baseline, and every month, up to 3 months	—

Countries

India

Contacts

Public ContactDR JAYABRATA PAL

The Calcutta Homoeopathic Medical College and Hospital

dr.jayabratapal@gmail.com7679752020

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026